EUROCALIN stands for “EUROpean Consortium for AntiCALINS as next generation high-affinity protein therapeutics”. The goal of the collaboration is to develop an exciting potential treatment for anemia into and through the first stage of clinical evaluation. The project started in August 2011 and will continue for four years.
Anticalins® are novel, next generation therapeutic proteins designed to bind and antagonize a wide spectrum of ligands. As funded by the grant, the Consortium will develop, manufacture and clinically test an Anticalin specific for hepcidin, a small peptide circulating in human blood that is considered to be a key regulator of iron homeostasis and, therefore, an important target for the treatment of multiple types of anemia. This Anticalin, called PRS-080, is the proprietary discovery of Pieris AG, an independent biotechnology company. Pieris has developed the PRS-080 molecule to the proof-of-concept stage and will oversee the consortium’s progress as project coordinator.
We invite you to discover more about the project itself, its partners, the disease and the progress of the project by exploring this web site!
Welcome to the web site of the EUROCALIN project!